# GSK (GSK) — Earnings

GSK · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/gsk/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $1.34 |
| EPS estimate | $1.28 |
| EPS surprise | +4.81% |
| Revenue surprise | +1.12% |
| Revenue | $11.2B |
| Revenue estimate | $11.1B |
| Reported | Jul 28, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1131399/000165495426006949/a1493o.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/eb2abc48-43dc-bf67-b3ae-3bb0db109602.html) |

GSK reported Q2 2026 results on July 28, 2026. Earnings per share were $1.34, ahead of the $1.28 estimate by 4.81%. Revenue was $11.2 billion, 1.12% above the $11.1 billion consensus. Compared with Q2 2025, EPS rose about 8% from $1.24 and revenue rose about 5.7% from $10.6 billion.

Annual EPS rose each year, from $3.39 in 2022 to $3.88 in 2023, $4.06 in 2024 and $4.60 in 2025. The first half of 2026 adds up to $2.60 per share, against $2.44 a year earlier. The fourth quarter has been the weakest of each year, at $0.58 to $0.74 per share, while the high in the table is Q3 2025 at $1.46. Quarterly revenue dropped from $12.2 billion in Q1 2022 to $8.3 billion in Q2 2022 and has ranged between $10.0 and $11.8 billion over the last six quarters. GSK beat the EPS estimate in all 20 quarters shown.

GSK reported its third quarter between October 27 and November 2 in each of the past five years. That points to late October or early November 2026 for the Q3 2026 report. It will show how results compare with Q3 2025's $1.46 per share.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 28, 2026 | $1.28 | $1.34 | 4.81% | $11.1B | $11.2B |
| Q1 2026 | Apr 29, 2026 | $1.15 | $1.26 | 8.75% | $10.2B | $10.3B |
| Q4 2025 | Feb 4, 2026 | $0.64 | $0.70 | 8.50% | $11.4B | $11.8B |
| Q3 2025 | Oct 29, 2025 | $1.26 | $1.46 | 15.87% | $11.0B | $11.3B |
| Q2 2025 | Jul 30, 2025 | $1.17 | $1.24 | 5.58% | $10.5B | $10.6B |
| Q1 2025 | Apr 30, 2025 | $1.04 | $1.20 | 14.83% | $9.7B | $10.0B |
| Q4 2024 | Feb 5, 2025 | $0.49 | $0.58 | 18.70% | $9.5B | $10.2B |
| Q3 2024 | Oct 30, 2024 | $1.15 | $1.29 | 12.25% | $10.5B | $10.4B |
| Q2 2024 | Jul 31, 2024 | $0.98 | $1.11 | 14.01% | $9.6B | $10.1B |
| Q1 2024 | May 1, 2024 | $0.92 | $1.08 | 16.85% | $8.9B | $9.2B |
| Q4 2023 | Jan 31, 2024 | $0.74 | $0.74 | 0.08% | $9.7B | $10.3B |
| Q3 2023 | Nov 1, 2023 | $1.11 | $1.22 | 9.72% | $9.4B | $9.9B |
| Q2 2023 | Jul 26, 2023 | $0.89 | $1.00 | 12.26% | $8.8B | $9.3B |
| Q1 2023 | Apr 26, 2023 | $0.83 | $0.92 | 11.44% | $8.1B | $8.7B |
| Q4 2022 | Feb 1, 2023 | $0.55 | $0.64 | 16.61% | $8.9B | $9.1B |
| Q3 2022 | Nov 2, 2022 | $0.90 | $1.08 | 19.64% | $8.3B | $9.0B |
| Q2 2022 | Jul 27, 2022 | $0.64 | $0.84 | 30.88% | $7.9B | $8.3B |
| Q1 2022 | Apr 27, 2022 | $0.79 | $0.83 | 4.98% | $11.7B | $12.2B |
| Q4 2021 | Feb 9, 2022 | $0.66 | $0.70 | 5.53% | $12.9B | $12.9B |
| Q3 2021 | Oct 27, 2021 | $0.79 | $1.01 | 28.03% | $11.9B | $12.4B |

## Frequently Asked Questions

### When did GSK (GSK) last report earnings?

GSK last reported on Jul 28, 2026, covering fiscal Q2 2026.

### Did GSK beat earnings estimates?

Yes. GSK reported EPS of $1.34 for Q2 2026 against a $1.28 estimate — a 4.81% beat.

### How much revenue did GSK report last quarter?

GSK reported $11.2B in revenue for Q2 2026, against a consensus estimate of $11.1B.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).